Dendreon has had some ugly quarters before. In fact, earnings have generally been a house of pain for investors in the company. Most of the big stock drops seen since launching prostate cancer vaccine Provenge have coincided with disappointing sales results.
In this video, health-care analyst David Williamson, breaks down the company's first-quarter results and looks at how, despite warning investors that sales would decline sequentially, even Dendreon's management appeared disappointed with the performance. Watch and find out what caused sluggish Provenge sales and whether Dendreon has a second life in it.
Resurgence, or dead cat bounce?
Shares of Dendreon have surged in recent months, with the stock gaining new life from the depths of late 2012. Has the company really solved its underlying problems, or are investors setting themselves up for more disappointment? Our new premium research report on Dendreon answers these questions, and many more, while also outlining just how Dendreon intends to regain its former glory. Claim your copy by clicking here now.
No comments:
Post a Comment